CliffBio
biologic

Asceniv

Immune Globulin Intravenous, Human-slra

Loss of exclusivityApril 2031projected — 12-year biologic exclusivity estimate
CompanyADMA Biologics →View the full company profile on CliffBio

Drug detail

Brand nameAsceniv
Active ingredientImmune Globulin Intravenous, Human-slra
Strength5G/50ML
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalApril 2019
Marketing statusRx

More from ADMA Biologics

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Asceniv patent cliff — loss of exclusivity April 2031 | CliffBio